Arrowhead Pharmaceuticals (ARWR) Total Non-Current Liabilities (2011 - 2026)

Arrowhead Pharmaceuticals' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• Quarterly Total Non-Current Liabilities rose 105.48% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 105.48% YoY) and the FY2025 annual result came in at $686.4 million, down 18.83% from the prior year.
• Total Non-Current Liabilities was $1.4 billion for Q1 2026 at Arrowhead Pharmaceuticals, up from $694.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $1.4 billion in Q1 2026 and bottomed at $112.5 million in Q1 2022.
• A 5-year average of $520.9 million and a median of $394.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities retreated 21.94% — and 2023, when it jumped 201.51%.
• Arrowhead Pharmaceuticals' Total Non-Current Liabilities stood at $373.1 million in 2022, then advanced by 4.22% to $388.8 million in 2023, then soared by 122.16% to $863.9 million in 2024, then fell by 19.66% to $694.1 million in 2025, then soared by 97.98% to $1.4 billion in 2026.
• Business Quant data shows ARWR's Total Non-Current Liabilities at $1.4 billion in Q1 2026, $694.1 million in Q4 2025, and $686.4 million in Q3 2025.